Tsumura & Co.
Tsumura & Co. (TSMRF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
tsmrf · pe ratio · data through Mar 31, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Tsumura & Co. (TSMRF) measures how much investors pay for each dollar of the company's trailing earnings. TSMRF's current PE ratio of 9.78x is calculated by dividing its stock price of $28.15 by its TTM earnings per share of $377.54. −25.0% discount vs 5Y avg 13.0x
Source: FMP · /ratios-ttm · /analyst-estimates · 2026-03-31
PE Ratio History
2007 – 2026 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 20 fiscal years · Front-end computedMinQ1 · 25%15.3x
MedianQ3 · 75%23.1x
Max
At 9.78x, TSMRF's current P/E is lower than in 10% of its annual fiscal year readings over the past 20 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Tsumura & Co.You TSMRF | $2.1B | 9.78x | -86.5% | $377.54 |
 Fagron N.V. ARSUF | $1.9B | 16.06x | -77.8% | $1.25 |
 CanSino Biologics Inc. CASBF | $1.4B | 309.29x | +327.6% | $0.11 |
 China Medical System Holdings Limited CHSYF | $2.3B | 15.75x | -78.2% | $0.60 |
 Curaleaf Holdings, Inc. CURLF | $3.0B | N/A | — | -$0.93 |
 Dermapharm Holding SE DMPHF | $2.9B | 13.70x | -81.1% | $2.46 |
 HUTCHMED (China) Limited HMDCF | $2.5B | 6.86x | -90.5% | $0.53 |
Industry Average 5 peers with valid PE | — | 72.33x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2026-03-31Latest FY2026 | 9.72x | $378.65 | -1.6% | |
2025-03-31 FY2025 | 9.88x | $427.15 | -44.6% | |
2024-03-31 FY2024 | 17.84x | $219.82 | +32.0% | |
2023-03-31 FY2023 | 13.51x | $215.63 | -5.1% | |
2022-03-31 FY2022 | 14.24x | $246.20 | -25.0% | |
2021-03-31 FY2021 | 18.97x | $200.40 | +22.6% | |
2020-03-31 FY2020 | 15.48x | $179.96 | -11.9% | |
2019-03-31 FY2019 | 17.56x | $190.87 | -6.2% | |
2018-03-31 FY2018 | 18.73x | $200.54 | +0.3% | |
2017-03-31 FY2017 | 18.67x | $179.45 | +7.6% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Tsumura & Co. (TSMRF) measures how much investors pay for each dollar of the company's trailing earnings. TSMRF's current PE ratio of 9.78x is calculated by dividing its stock price of $28.15 by its TTM earnings per share of $377.54.
Frequently asked questions
TSMRF pe ratio · 6 questionsTSMRF's current PE ratio is 9.78x as of 2026-06-09, based on a stock price of $28.15 and TTM EPS of $377.54. Data sourced from Financial Modeling Prep via TSMRF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Tsumura & Co. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09